Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 14Recruiting 8Terminated 6Withdrawn 4Active not recruiting 3Unknown 2

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 4

Interventions

pembrolizumab 61Radiotherapy 55Gemcitabine 51Paclitaxel 49Cyclophosphamide 48Cisplatin 48Carboplatin 45Dexamethasone 37Bevacizumab 37Nivolumab 35Fluorouracil 34Docetaxel 34Oxaliplatin 33durvalumab 32Rituximab 28Magnetic Resonance Spectroscopy 28Leucovorin 28Drug Therapy 25Pemetrexed 24Doxorubicin 24Capecitabine 24atezolizumab 22Radiation 20Cytarabine 20Radiosurgery 19Prednisone 19Etoposide 19Irinotecan 17Bortezomib 17Cetuximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Withdrawn × gallium 68 PSMA-11 × Clear all
NCT04243941 2024-03-21

PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer

UNC Lineberger Comprehensive Cancer Center

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT05034562 2024-03-07

Gallium-68 PSMA-11 PET in Participants With Prostate Cancer

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT04483414 2023-05-19

68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer

University of Texas Southwestern Medical Center

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT02810886 2017-08-22

ProsPERo

Jules Bordet Institute

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡